Abstract
Summary
The global Long-acting Antipsychotic market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Antipsychotic Industry Forecast” looks at past sales and reviews total world Long-acting Antipsychotic sales in 2023, providing a comprehensive analysis by region and market sector of projected Long-acting Antipsychotic sales for 2024 through 2030. With Long-acting Antipsychotic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Antipsychotic industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Antipsychotic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Antipsychotic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Antipsychotic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Antipsychotic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Antipsychotic.
United States market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Long-acting Antipsychotic players cover Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Antipsychotic market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Aripiprazole
Haloperidol
Paliperidone
Risperidone
Olanzapine
Others
Segmentation by Application:
Schizophrenia
Bipolar Disorder
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Oakwood Labs
Teva
MedinCell
Janssen
Otsuka America Pharmaceutical, Inc.
Lundbeck
Eli Lilly
Alkermes
Par Pharmaceutical
AbbVie
Luye Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting Antipsychotic market?
What factors are driving Long-acting Antipsychotic market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Antipsychotic market opportunities vary by end market size?
How does Long-acting Antipsychotic break out by Type, by Application?
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Antipsychotic Industry Forecast” looks at past sales and reviews total world Long-acting Antipsychotic sales in 2023, providing a comprehensive analysis by region and market sector of projected Long-acting Antipsychotic sales for 2024 through 2030. With Long-acting Antipsychotic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Antipsychotic industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Antipsychotic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Antipsychotic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Antipsychotic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Antipsychotic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Antipsychotic.
United States market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Long-acting Antipsychotic players cover Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Antipsychotic market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Aripiprazole
Haloperidol
Paliperidone
Risperidone
Olanzapine
Others
Segmentation by Application:
Schizophrenia
Bipolar Disorder
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Oakwood Labs
Teva
MedinCell
Janssen
Otsuka America Pharmaceutical, Inc.
Lundbeck
Eli Lilly
Alkermes
Par Pharmaceutical
AbbVie
Luye Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting Antipsychotic market?
What factors are driving Long-acting Antipsychotic market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Antipsychotic market opportunities vary by end market size?
How does Long-acting Antipsychotic break out by Type, by Application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Long-acting Antipsychotic Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Long-acting Antipsychotic by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Long-acting Antipsychotic by Country/Region, 2019, 2023 & 2030
2.2 Long-acting Antipsychotic Segment by Type
2.2.1 Aripiprazole
2.2.2 Haloperidol
2.2.3 Paliperidone
2.2.4 Risperidone
2.2.5 Olanzapine
2.2.6 Others
2.3 Long-acting Antipsychotic Sales by Type
2.3.1 Global Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
2.3.2 Global Long-acting Antipsychotic Revenue and Market Share by Type (2019-2024)
2.3.3 Global Long-acting Antipsychotic Sale Price by Type (2019-2024)
2.4 Long-acting Antipsychotic Segment by Application
2.4.1 Schizophrenia
2.4.2 Bipolar Disorder
2.4.3 Others
2.5 Long-acting Antipsychotic Sales by Application
2.5.1 Global Long-acting Antipsychotic Sale Market Share by Application (2019-2024)
2.5.2 Global Long-acting Antipsychotic Revenue and Market Share by Application (2019-2024)
2.5.3 Global Long-acting Antipsychotic Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Long-acting Antipsychotic Breakdown Data by Company
3.1.1 Global Long-acting Antipsychotic Annual Sales by Company (2019-2024)
3.1.2 Global Long-acting Antipsychotic Sales Market Share by Company (2019-2024)
3.2 Global Long-acting Antipsychotic Annual Revenue by Company (2019-2024)
3.2.1 Global Long-acting Antipsychotic Revenue by Company (2019-2024)
3.2.2 Global Long-acting Antipsychotic Revenue Market Share by Company (2019-2024)
3.3 Global Long-acting Antipsychotic Sale Price by Company
3.4 Key Manufacturers Long-acting Antipsychotic Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Long-acting Antipsychotic Product Location Distribution
3.4.2 Players Long-acting Antipsychotic Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Long-acting Antipsychotic by Geographic Region
4.1 World Historic Long-acting Antipsychotic Market Size by Geographic Region (2019-2024)
4.1.1 Global Long-acting Antipsychotic Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Long-acting Antipsychotic Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Long-acting Antipsychotic Market Size by Country/Region (2019-2024)
4.2.1 Global Long-acting Antipsychotic Annual Sales by Country/Region (2019-2024)
4.2.2 Global Long-acting Antipsychotic Annual Revenue by Country/Region (2019-2024)
4.3 Americas Long-acting Antipsychotic Sales Growth
4.4 APAC Long-acting Antipsychotic Sales Growth
4.5 Europe Long-acting Antipsychotic Sales Growth
4.6 Middle East & Africa Long-acting Antipsychotic Sales Growth
5 Americas
5.1 Americas Long-acting Antipsychotic Sales by Country
5.1.1 Americas Long-acting Antipsychotic Sales by Country (2019-2024)
5.1.2 Americas Long-acting Antipsychotic Revenue by Country (2019-2024)
5.2 Americas Long-acting Antipsychotic Sales by Type (2019-2024)
5.3 Americas Long-acting Antipsychotic Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-acting Antipsychotic Sales by Region
6.1.1 APAC Long-acting Antipsychotic Sales by Region (2019-2024)
6.1.2 APAC Long-acting Antipsychotic Revenue by Region (2019-2024)
6.2 APAC Long-acting Antipsychotic Sales by Type (2019-2024)
6.3 APAC Long-acting Antipsychotic Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Long-acting Antipsychotic by Country
7.1.1 Europe Long-acting Antipsychotic Sales by Country (2019-2024)
7.1.2 Europe Long-acting Antipsychotic Revenue by Country (2019-2024)
7.2 Europe Long-acting Antipsychotic Sales by Type (2019-2024)
7.3 Europe Long-acting Antipsychotic Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Long-acting Antipsychotic by Country
8.1.1 Middle East & Africa Long-acting Antipsychotic Sales by Country (2019-2024)
8.1.2 Middle East & Africa Long-acting Antipsychotic Revenue by Country (2019-2024)
8.2 Middle East & Africa Long-acting Antipsychotic Sales by Type (2019-2024)
8.3 Middle East & Africa Long-acting Antipsychotic Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Long-acting Antipsychotic
10.3 Manufacturing Process Analysis of Long-acting Antipsychotic
10.4 Industry Chain Structure of Long-acting Antipsychotic
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Long-acting Antipsychotic Distributors
11.3 Long-acting Antipsychotic Customer
12 World Forecast Review for Long-acting Antipsychotic by Geographic Region
12.1 Global Long-acting Antipsychotic Market Size Forecast by Region
12.1.1 Global Long-acting Antipsychotic Forecast by Region (2025-2030)
12.1.2 Global Long-acting Antipsychotic Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Long-acting Antipsychotic Forecast by Type (2025-2030)
12.7 Global Long-acting Antipsychotic Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Oakwood Labs
13.1.1 Oakwood Labs Company Information
13.1.2 Oakwood Labs Long-acting Antipsychotic Product Portfolios and Specifications
13.1.3 Oakwood Labs Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Oakwood Labs Main Business Overview
13.1.5 Oakwood Labs Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Long-acting Antipsychotic Product Portfolios and Specifications
13.2.3 Teva Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 MedinCell
13.3.1 MedinCell Company Information
13.3.2 MedinCell Long-acting Antipsychotic Product Portfolios and Specifications
13.3.3 MedinCell Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 MedinCell Main Business Overview
13.3.5 MedinCell Latest Developments
13.4 Janssen
13.4.1 Janssen Company Information
13.4.2 Janssen Long-acting Antipsychotic Product Portfolios and Specifications
13.4.3 Janssen Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Janssen Main Business Overview
13.4.5 Janssen Latest Developments
13.5 Otsuka America Pharmaceutical, Inc.
13.5.1 Otsuka America Pharmaceutical, Inc. Company Information
13.5.2 Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Product Portfolios and Specifications
13.5.3 Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Otsuka America Pharmaceutical, Inc. Main Business Overview
13.5.5 Otsuka America Pharmaceutical, Inc. Latest Developments
13.6 Lundbeck
13.6.1 Lundbeck Company Information
13.6.2 Lundbeck Long-acting Antipsychotic Product Portfolios and Specifications
13.6.3 Lundbeck Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Lundbeck Main Business Overview
13.6.5 Lundbeck Latest Developments
13.7 Eli Lilly
13.7.1 Eli Lilly Company Information
13.7.2 Eli Lilly Long-acting Antipsychotic Product Portfolios and Specifications
13.7.3 Eli Lilly Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Eli Lilly Main Business Overview
13.7.5 Eli Lilly Latest Developments
13.8 Alkermes
13.8.1 Alkermes Company Information
13.8.2 Alkermes Long-acting Antipsychotic Product Portfolios and Specifications
13.8.3 Alkermes Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Alkermes Main Business Overview
13.8.5 Alkermes Latest Developments
13.9 Par Pharmaceutical
13.9.1 Par Pharmaceutical Company Information
13.9.2 Par Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
13.9.3 Par Pharmaceutical Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Par Pharmaceutical Main Business Overview
13.9.5 Par Pharmaceutical Latest Developments
13.10 AbbVie
13.10.1 AbbVie Company Information
13.10.2 AbbVie Long-acting Antipsychotic Product Portfolios and Specifications
13.10.3 AbbVie Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 AbbVie Main Business Overview
13.10.5 AbbVie Latest Developments
13.11 Luye Pharmaceutical
13.11.1 Luye Pharmaceutical Company Information
13.11.2 Luye Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
13.11.3 Luye Pharmaceutical Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Luye Pharmaceutical Main Business Overview
13.11.5 Luye Pharmaceutical Latest Developments
14 Research Findings and Conclusion